These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 891391)

  • 41. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
    Mertz DP
    MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disease-specific noncompliance with drug treatment as a cause of persistent hyperuricemia and gout in anorexia nervosa.
    Gröbner W; Walter-Sack I; de Vries JX
    Eur J Med Res; 1998 Feb; 3(1-2):77-80. PubMed ID: 9512972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Analysis of the hypo-uricemic action of benzbromarone in 40 cases of gouty and non-gouty hyperuricemia].
    Famaey JP; Vandenabeele G
    J Belge Rhumatol Med Phys; 1970; 25(1):5-9. PubMed ID: 5486285
    [No Abstract]   [Full Text] [Related]  

  • 44. Drug treatment of gout.
    Kelley WN; Wyngaarden JB
    Semin Drug Treat; 1971 Sep; 1(2):119-47. PubMed ID: 4949305
    [No Abstract]   [Full Text] [Related]  

  • 45. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
    Mertz DP
    Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects].
    Yamanaka H
    Nihon Rinsho; 2003 Jan; 61 Suppl 1():202-8. PubMed ID: 12629718
    [No Abstract]   [Full Text] [Related]  

  • 47. [Treatment of gout].
    Yoshimura T
    Geka Chiryo; 1970 Mar; 22(3):311-6. PubMed ID: 5467649
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].
    Arntz HR; Dreykluft HR; Leonhardt H
    Fortschr Med; 1979 Jul; 97(27):1212-4. PubMed ID: 457017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Editorial: Therapy of gout nowadays (author's transl)].
    Mertz DP
    Schweiz Rundsch Med Prax; 1974 Oct; 63(40):1185-7. PubMed ID: 4445089
    [No Abstract]   [Full Text] [Related]  

  • 50. [Hyperuricemia due to hypoxanthine-guanine-phosphoribosyltransferase deficiency].
    Blétry O; Cartier P; Hamet M; Clauvel JP
    Nouv Presse Med; 1974 Apr; 3(16):995-9. PubMed ID: 4836472
    [No Abstract]   [Full Text] [Related]  

  • 51. [Use of sorption for the correction of hyperuricemia in the combined treatment of gout].
    Matulis AA; Bareĭkene IP; Venalis AI
    Ter Arkh; 1987; 59(12):17-9. PubMed ID: 3447284
    [No Abstract]   [Full Text] [Related]  

  • 52. [Differential indications for uricosuric drugs and allopurinol].
    Gröbner W; Zöllner N
    Klin Wochenschr; 1989 Mar; 67(5):313-5. PubMed ID: 2709742
    [No Abstract]   [Full Text] [Related]  

  • 53. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
    Matzkies F; Neuwirth R; Berg G
    Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
    Stocker SL; Graham GG; McLachlan AJ; Williams KM; Day RO
    J Rheumatol; 2011 May; 38(5):904-10. PubMed ID: 21285173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical images: Divergent patterns of joint remodeling following effective urate-lowering therapy in tophaceous gout.
    Dalbeth N; Doyle A; McQueen FM
    Arthritis Rheum; 2011 Jan; 63(1):266. PubMed ID: 20722028
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gout due to xanthine derivatives.
    Toda K; Goriki K; Ochiai M; Tokunou H; Uehara S; Takahashi H; Okusaki K
    Br J Rheumatol; 1997 Oct; 36(10):1131-2. PubMed ID: 9374937
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
    Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Uricoeliminating or urico-inhibiting agents? Reasons for a choice].
    Cottin S; Prost A
    Sem Hop; 1972 May; 48(24):1739-42. PubMed ID: 4340887
    [No Abstract]   [Full Text] [Related]  

  • 60. [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
    Zöllner N; Griebsch A; Fink JK
    Dtsch Med Wochenschr; 1970 Nov; 95(48):2405-12. PubMed ID: 5480261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.